Invitae Corporation

OTCPK:NVTA.Q Rapporto sulle azioni

Cap. di mercato: US$114.6k

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Invitae Performance dei guadagni passati

Il passato criteri di controllo 0/6

Invitae's earnings have been declining at an average annual rate of -53.3%, while the Healthcare industry saw earnings growing at 5% annually. Revenues have been growing at an average rate of 26.5% per year.

Informazioni chiave

-53.3%

Tasso di crescita degli utili

-34.1%

Tasso di crescita dell'EPS

Healthcare Crescita del settore8.5%
Tasso di crescita dei ricavi26.5%
Rendimento del capitale proprion/a
Margine netto-299.1%
Ultimo aggiornamento sui guadagni30 Sep 2023

Aggiornamenti sulle prestazioni recenti

Recent updates

Cautious Investors Not Rewarding Invitae Corporation's (NYSE:NVTA) Performance Completely

Dec 20
Cautious Investors Not Rewarding Invitae Corporation's (NYSE:NVTA) Performance Completely

Invitae: Revenue Troubles Build

Aug 09

Invitae Is Treading In Competitive Waters

Jul 16

Invitae Corporation's (NYSE:NVTA) Prospects Need A Boost To Lift Shares

Jun 26
Invitae Corporation's (NYSE:NVTA) Prospects Need A Boost To Lift Shares

Invitae: What Happened At The JP Morgan Health Conference

Jan 19

Invitae guides Q4 revenue above estimates

Jan 09

Invitae Likely Hasn't Reached The Bottom Yet

Dec 15

Invitae: This Turnaround Could Be Painful

Nov 15

Invitae GAAP EPS of -$1.27 misses by $0.43, revenue of $133.54M beats by $2.16M

Nov 08

Invitae Stock: Losses And Debt Suggest Bearish Sentiment Is Deserved

Sep 22

Why Invitae Corporation Could Underperform

Aug 17

Invitae maintains 2022 financial guidance as Q2 results beat on top and bottom lines

Aug 09

Ripartizione dei ricavi e delle spese

Come Invitae guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.


Storia dei guadagni e delle entrate

OTCPK:NVTA.Q Ricavi, spese e utili (USD Millions )
DataRicaviGuadagniSpese G+ASpese di R&S
30 Sep 23482-1,441361256
30 Jun 23494-800371285
31 Mar 23510-3,117389336
31 Dec 22516-3,106411402
30 Sep 22520-3,212436462
30 Jun 22501-3,109484473
31 Mar 22481-451462464
31 Dec 21460-379474416
30 Sep 21435-408599405
30 Jun 21389-313522345
31 Mar 21319-613496284
31 Dec 20280-602438241
30 Sep 20245-445254171
30 Jun 20233-421243180
31 Mar 20241-303230160
31 Dec 19217-242201142
30 Sep 19196-195176107
30 Jun 19177-14815176
31 Mar 19161-13113066
31 Dec 18148-12912663
30 Sep 18128-14011961
30 Jun 18109-13611556
31 Mar 1886-13310452
31 Dec 1768-1239146
30 Sep 1752-1087745
30 Jun 1740-1056545
31 Mar 1731-1025744
31 Dec 1625-1005245
30 Sep 1619-1004844
30 Jun 1615-974544
31 Mar 1611-974345
31 Dec 158-903943
30 Sep 156-813538
30 Jun 154-713132
31 Mar 153-572626
31 Dec 142-472122
30 Sep 141-401621
30 Jun 141-351320
31 Mar 140-291018
31 Dec 130-25816

Guadagni di qualità: NVTA.Q is currently unprofitable.

Margine di profitto in crescita: NVTA.Q is currently unprofitable.


Flusso di cassa libero e analisi degli utili


Analisi della crescita degli utili nel passato

Andamento degli utili: NVTA.Q is unprofitable, and losses have increased over the past 5 years at a rate of 53.3% per year.

Accelerare la crescita: Unable to compare NVTA.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable

Guadagni vs Settore: NVTA.Q is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (6%).


Rendimento del capitale proprio

ROE elevato: NVTA.Q's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Rendimento delle attività


Rendimento del capitale investito


Scoprire le aziende con forti performance passate